Core Viewpoint - The article discusses a complaint from a client, Ms. Zhang, regarding her cancer diagnosis after ten years of health check-ups with Aikang Group, raising questions about the accuracy of the previous test results [1][2]. Group 1: Client Complaint and Response - Ms. Zhang underwent annual health check-ups from 2013 to 2023, with normal results for the cancer marker CEA, but was diagnosed with advanced kidney cancer in 2024 [1]. - Aikang Group expressed sympathy for Ms. Zhang's condition and committed to supporting her during treatment, while also initiating an internal review of her medical records [1][2]. - The company plans to collaborate with a third-party authority for verification and analysis of the test results, agreeing to take responsibility if found at fault [2]. Group 2: Cancer Detection and Growth - The article explains that cancer detection depends on various factors, including the timing of tests, methods used, and the expertise of medical professionals [2]. - It cites a study indicating that the average growth rate of clinically significant kidney cancer is 2.13 cm per year, with variability based on individual factors [2]. - Ms. Zhang's 2023 report indicated potential issues with her kidneys, and the size of the tumor in her 2024 pathology report fell within the expected growth range for cancer [3][4]. Group 3: Limitations of Current Testing - The article highlights that there are currently no recognized serum tumor markers for the early diagnosis of renal cell carcinoma, indicating that the CEA test results may not be relevant for assessing the risk of kidney cancer [4].

Core Viewpoint - The incident of a woman being diagnosed with late-stage cancer despite ten years of normal health check-ups has raised concerns, prompting the company to clarify its position on cancer detection and health screenings [1] Group 1: Cancer Detection Process - The occurrence of cancer involves a process that includes genetic mutations, methylation abnormalities, inactivation of tumor suppressor genes, and activation of oncogenes [1] - The ability to detect cancer depends on various factors such as the timing of the health check, detection methods, equipment used, and the expertise of the medical professionals [1] - Some cancers may not be detectable at certain times due to the limitations of the testing methods employed during that period [1] Group 2: Responsibility and Accountability - The company emphasizes that its health check reports accurately reflect the results of the examinations conducted at the time [1] - In cases where detection fails, the company will engage third-party authoritative institutions and experts for analysis and validation of the reasons behind the undetected cancer [1] - Should it be determined that the company is at fault, it commits to taking responsibility and will not evade accountability [1]

Core Viewpoint - The company, Aikang Group, has responded to concerns regarding a case where a woman was diagnosed with late-stage cancer despite having normal health check results for ten years, emphasizing the complexity of cancer detection and the need for third-party analysis [1] Group 1 - Aikang Group acknowledges that cancer development involves a process influenced by genetic mutations, methylation abnormalities, and the activation or inactivation of oncogenes and tumor suppressor genes [1] - The company states that the effectiveness of health checks can vary based on the timing, methods, equipment used, and the expertise of the medical professionals involved [1] - Aikang Group commits to engaging a third-party authority for analysis to determine the reasons behind the undetected cancer and assures that it will take responsibility if found liable [1]

Group 1 - The core issue involves allegations of misdiagnosis and missed cancer detection by Aikang Guobin, as a lawyer claims to have undergone health check-ups for ten years without being informed of cancer risks, leading to a late-stage cancer diagnosis in 2024 [1] - Aikang Guobin has acknowledged receipt of the lawyer's letter and is currently discussing how to address the situation, but has not provided a direct response regarding the allegations of misdiagnosis or missed diagnoses [1] - The company, Aikang Guobin, was established in September 2004 with a registered capital of 50 million RMB, and its business scope includes hospital management, corporate management, and health consulting services [1] Group 2 - Aikang Guobin has faced multiple medical disputes, including a lawsuit in May 2023 related to a contract dispute over a health check fee and damages due to missed diagnoses [2] - In March 2025, a subsidiary of Aikang Guobin was fined for failing to comply with medical record writing standards and for issues related to the quality of health check reports [2] - The CEO of Aikang Guobin previously highlighted industry issues, claiming that some institutions engage in fraudulent practices, such as having nurses impersonate doctors and discarding blood samples after testing [2][3]

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 28, 2025, at 14:50 in Shanghai [1][2] - The meeting will combine on-site voting and online voting, with online voting available from 9:15 to 15:00 on the same day [1][2] Voting Procedures - Shareholders can choose either on-site voting or online voting, and duplicate votes will be counted based on the first submission [2] - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [6][7] Agenda Items - The meeting will review several proposals, including the issuance of shares for asset acquisition and related transactions [4][12] - Proposals require a two-thirds majority of valid votes from attending shareholders, with related shareholders required to abstain from voting on certain items [6][12] Compliance and Reporting - The proposals have been approved by the company's board and supervisory committee, and details were published in various financial news outlets [5][12] - The company will ensure compliance with relevant regulations regarding asset restructuring and share issuance [5][13]

Core Insights - The report highlights the increasing health issues among the population in Beijing, emphasizing the importance of regular health check-ups [1][2][8] - The data collected from 1.483 million health check-ups reveals alarming trends in various health indicators, particularly among different age groups and genders [1][5] Group 1: Health Issues Identified - Bone density reduction/osteoporosis has become the leading health concern in Beijing, with a detection rate of 53.64% [2] - The detection rate for increased Body Mass Index (BMI) and thyroid nodules also exceeds 50%, marking them as significant health threats [2] - Fatty liver, carotid artery abnormalities, and elevated total cholesterol levels have detection rates above 30% [2] Group 2: Gender-Specific Health Trends - Male participants show a higher prevalence of increased BMI, with detection rates nearing 70%, and a fatty liver detection rate of 55.11% among men aged 40-49 [5] - In contrast, females have a higher detection rate of thyroid nodules at over 57%, with a significant increase in breast nodules from 25.33% in 2021 to 40.53% [5] Group 3: Cancer Detection Rates - Thyroid cancer has the highest detection rate among the cancer cases identified, exceeding 48%, with a total of 1,535 cancer diagnoses among the health check-up participants [8] - The cancer detection rate among individuals under 40 years old is concerning, with nearly one-third of the diagnosed cases falling into this age group [8] - The report suggests that the high detection rate of thyroid cancer is due to the widespread use of ultrasound in health check-ups, with a participation rate of 78.85% for thyroid ultrasounds [8]

投资者提问：想请问公司未来是否有与公立三甲医院开展合作的规划？若能获得公立三甲医院对公司体 检结果的认可，将有助于公司在团体客户、健康管理等领域拓展更多业务合作。能否透露公司在这方面 的战略布局及推进计划？ 证券之星消息，美年健康(002044)06月18日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 美年健康回复：尊敬的投资者，您好！公司持续积极推动与公立三甲医院的交流合作。截止目前，公司 各地分院与当地三甲医院等机构共建超过350个医联体/健联体，在技术交流、医疗设备和专家资源共 享、人才培养、患者转诊、应急救援等方面开展合作。在结果互认方面，公司每年结合各地政策情况， 积极参与推动检验结果互认的有关工作，目前公司旗下数十家分院获选省、市级临床检验结果互认机 构，部分分院获选省、市级超声结果互认机构与放射结果互认机构。未来，公司继续积极响应政策号 召，持续积极参与推进更多分院医疗检查检验结果互认工作，为就医流程优化和用户体验升级不懈努 力。同时，公司将持续深化学科建设，加强与三甲医院、 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002044 证券简称：美年健康 公告编号：2025-028 美年大健康产业控股股份有限公司 3、会议召开的合法、合规性：本次股东大会的召集、召开及审议事项符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》等法律、行政法规及《公司章程》等规 定，提案内容明确并在法定期限内公告。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年5月14日（星期三）下午14:30。 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024年度股东大会现场会议的召开地点为上海市 静安区灵石路697号健康智谷9号楼三楼公司会议室，敬请投资者特别留意。 根据公司于2025年4月15日召开的第九届董事会第八次会议，定于2025年5月14日召开公司2024年度股东 大会，本次股东大会将采用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开2024年度 股东大会的通知》（公告 ...

4月25日有消费者投诉称，自己于2024年12月12日在爱康国宾体检，工作人员推荐了基因检测，两项目收费1200元， 工作人员声称，结果出来会有专业人员给消费者打电话解读报告，自己才买的，但是报告出来至今没有任何人给消 费者打电话解读报告，售后一塌糊涂，因此自己希望能够全额退款。 DoNews5月8日消息，近日，DoNews发现，在黑猫平台，爱康国宾的相关投诉超1200件，其中大部分都与过度推 销，体检结果不准有关。 不止病人受罪且花费巨大，其他检查费用不论，手术花费4万有余，且后期放疗费用也需要4-5万。 拨打爱康售后电 话，告知诉求为承担一半的手术费用并退回体检费用。 前期爱康一直敷衍了事，不予正面解决，后续持续拨打售后电话后才安排专人处理，对接过程中从未对病人病情进 行关心，都是推卸己方责任，且过程都是自己在催促，后期也是一句不予赔付了事。 2024年11月4日，有消费者投诉称，因岳父身体消瘦明显，自己带岳父于2024年3月15日去武汉爱康国宾体检，体检 费用1559元，体检报告显示除个别小问题外体检无异常。因为相信爱康体检的专业性，在家拖延了3个月，6月才因 持续消瘦去医院查找病因，最终于8月份确诊为 ...

Core Viewpoint - Meinian Health has reported strong growth in its AI-driven healthcare services, with Q1 2025 revenue reaching 1.754 billion yuan, including over 54 million yuan from AI technology, marking a 71.76% increase year-on-year, indicating a significant shift from technological exploration to large-scale application in the "AI + healthcare" model [1] Group 1: AI Empowerment in Health Management - Meinian Health's core strategy revolves around "AI + healthcare," transforming the entire health check process into an intelligent service system, covering pre-examination, examination, and post-examination stages [1] - In the pre-examination phase, AI technology customizes health check packages based on individual and group client data, ensuring precision and relevance in health assessments [2] - During the examination, the company has implemented intelligent management tools that enhance customer experience and facilitate seamless transitions from routine screenings to precise diagnostics [2] - Post-examination services leverage AI systems like "Health Xiaomei" to provide personalized health management, with significant improvements in report accuracy and processing efficiency [2] Group 2: Innovation and Competitive Advantage - Meinian Health focuses on building eight core disciplines, utilizing AI to create unique competitive barriers, particularly in ultrasound technology [3] - The company has introduced specialized AI products for various health management areas, enhancing screening efficiency and promoting systematic solutions for early detection [4] - Innovative screening models, such as the "CT One Scan Multiple Checks" system, integrate multiple assessments into a single examination, significantly improving efficiency [4] Group 3: Expansion of Post-Examination Market - The company is transitioning from traditional health check services to comprehensive lifecycle health management, activating deeper individual client needs through innovative operational strategies [5] - Meinian Health is enhancing customer engagement by providing a one-stop solution that includes health checks, specialized examinations, health management, and insurance [6] Group 4: Industry Impact and Future Outlook - Meinian Health is evolving from a health check service provider to an AI health management solution platform, establishing a dual engine for performance growth through specialized early screening products and intelligent health management [7] - The company aims to leverage AI technology to expand into trillion-level markets, focusing on senior health, health management, and data elements, positioning itself as a leader in the digital health management era [8]